Oslo, Norway

Helge Tolleshaug

USPTO Granted Patents = 6 

Average Co-Inventor Count = 4.7

ph-index = 4

Forward Citations = 408(Granted Patents)


Location History:

  • Oslo, NO (2001 - 2008)
  • Olso, NO (2001 - 2012)

Company Filing History:


Years Active: 2001-2012

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Helge Tolleshaug: Innovator in Diagnostic Contrast Agents

Introduction

Helge Tolleshaug is a notable inventor based in Oslo, Norway. He has made significant contributions to the field of diagnostic imaging through his innovative work on contrast agents. With a total of six patents to his name, Tolleshaug's inventions have advanced the capabilities of in vivo imaging.

Latest Patents

Tolleshaug's latest patents focus on novel compounds and pharmaceutical compositions that exhibit affinity for proteoglycans. One of his inventions provides compounds that comprise an amino acid-based core unit linked to positively charged moieties. These compounds are designed to be used as diagnostic contrast agents for imaging proteoglycans, such as heparan sulphate proteoglycans. Another patent presents a composition of matter characterized by a formula that includes a vector moiety with affinity for angiogenesis-related endothelial cell receptors, enhancing the detection capabilities in imaging.

Career Highlights

Throughout his career, Helge Tolleshaug has worked with prominent companies in the imaging sector, including Nycomed Imaging AS and Amersham Health AS. His work has been instrumental in developing advanced imaging technologies that improve diagnostic accuracy.

Collaborations

Tolleshaug has collaborated with notable professionals in his field, including Jo Klaveness and Alan Cuthbertson. These collaborations have contributed to the success and innovation of his projects.

Conclusion

Helge Tolleshaug's contributions to the field of diagnostic imaging through his patents and collaborations highlight his role as a leading inventor. His work continues to influence advancements in medical imaging technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…